Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
$0.39
$0.39
$0.23
$2.83
$26.62M1.55943,490 shsN/A
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$0.80
+0.7%
$0.83
$0.66
$2.43
$92.86M0.862.67 million shs679,404 shs
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$2.59
+1.0%
$1.83
$0.91
$6.05
$216.39M2.152.61 million shs1.91 million shs
Elutia Inc. stock logo
ELUT
Elutia
$2.11
-2.5%
$1.90
$1.61
$5.12
$86.56M0.8842,605 shs4,737 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
0.00%0.00%0.00%0.00%0.00%
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
+0.74%+9.34%+2.69%+2.46%-42.37%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
+0.98%+21.93%+42.03%+150.97%-44.53%
Elutia Inc. stock logo
ELUT
Elutia
-2.55%+13.78%+8.51%-22.32%-51.83%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
0.1657 of 5 stars
0.00.00.03.80.60.00.0
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
3.7652 of 5 stars
3.31.00.04.50.62.50.6
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
4.2967 of 5 stars
3.23.00.04.32.52.50.6
Elutia Inc. stock logo
ELUT
Elutia
3.9183 of 5 stars
3.55.00.00.03.23.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
0.00
N/AN/AN/A
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
2.67
Moderate Buy$4.68484.69% Upside
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.31
Hold$4.7081.82% Upside
Elutia Inc. stock logo
ELUT
Elutia
3.00
Buy$8.00280.05% Upside

Current Analyst Ratings Breakdown

Latest AGTC, ELUT, CHRS, and EDIT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$8.00 ➝ $4.00
5/9/2025
Elutia Inc. stock logo
ELUT
Elutia
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $8.00
4/29/2025
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
4/29/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
4/28/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$3.00
4/28/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$3.00
4/24/2025
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.50 ➝ $1.05
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
$320K83.19N/AN/A$0.26 per share1.51
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$272.25M0.34$0.29 per share2.73($1.14) per share-0.70
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$32.31M6.70N/AN/A$1.63 per share1.59
Elutia Inc. stock logo
ELUT
Elutia
$24.38M3.55N/AN/A($1.31) per share-1.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
-$68.94M-$1.46N/AN/AN/AN/A-192.90%-92.54%N/A
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$28.51M-$1.13N/AN/AN/A-66.30%N/A-26.51%8/6/2025 (Estimated)
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$237.09M-$3.04N/AN/AN/A-701.06%-139.24%-63.87%8/6/2025 (Estimated)
Elutia Inc. stock logo
ELUT
Elutia
-$53.95M-$1.93N/AN/AN/A-168.23%N/A-96.70%7/28/2025 (Estimated)

Latest AGTC, ELUT, CHRS, and EDIT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
-$0.31-$0.35-$0.04-$0.49$59.79 million$7.60 million
5/12/2025Q1 2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 million
5/8/2025Q1 2025
Elutia Inc. stock logo
ELUT
Elutia
-$0.20-$0.21-$0.01-$0.21$6.65 million$6.03 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
N/AN/AN/AN/AN/A
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
N/AN/AN/AN/AN/A
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/AN/AN/AN/AN/A
Elutia Inc. stock logo
ELUT
Elutia
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
0.39
1.40
1.40
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
N/A
1.22
1.20
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/A
3.08
3.08
Elutia Inc. stock logo
ELUT
Elutia
N/A
0.81
0.70

Institutional Ownership

CompanyInstitutional Ownership
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
22.05%
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
72.82%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
71.90%
Elutia Inc. stock logo
ELUT
Elutia
74.03%

Insider Ownership

CompanyInsider Ownership
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
4.10%
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
8.08%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.10%
Elutia Inc. stock logo
ELUT
Elutia
27.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
8367.63 million64.86 millionOptionable
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
330115.93 million106.57 millionOptionable
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
23083.71 million81.96 millionOptionable
Elutia Inc. stock logo
ELUT
Elutia
18041.12 million29.77 millionNot Optionable

Recent News About These Companies

Medical Device Network Excellence Awards 2025: Elutia
Elutia Inc. (ELUT) Q1 2025 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Applied Genetic Technologies stock logo

Applied Genetic Technologies NASDAQ:AGTC

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

Coherus Oncology stock logo

Coherus Oncology NASDAQ:CHRS

$0.80 +0.01 (+0.74%)
Closing price 07/3/2025 03:39 PM Eastern
Extended Trading
$0.78 -0.03 (-3.12%)
As of 07/3/2025 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Editas Medicine stock logo

Editas Medicine NASDAQ:EDIT

$2.58 +0.03 (+0.98%)
Closing price 07/3/2025 03:48 PM Eastern
Extended Trading
$2.60 +0.01 (+0.39%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Elutia stock logo

Elutia NASDAQ:ELUT

$2.10 -0.06 (-2.55%)
Closing price 07/3/2025 01:56 PM Eastern
Extended Trading
$2.09 -0.02 (-0.71%)
As of 07/3/2025 04:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.